AGREE_ Cyber Security Market -With a cumulative market valued at $65.5 billion
DD From Last Data:
11/14 CUPID data show that heart failure, which is a progressive disease, became stabilized in MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function significantly improved or remained the same while these parameters deteriorated substantially with patients treated with placebo and concurrent optimal drug and device therapy.The safety profile from this study was very favorable, with no significant side-effects from MYDICAR® therapy
Cyber Security Market Forecast 2014-2024
LONDON /PRNewswire/ -- With attackers able to strike from anywhere and inflict damage on a significant(but often unnoticed) scale, the threat has never been greater. As a consequence, visigain has assessed that the value of the global Cyber Security market in 2014 will reach $76.68bn and will continue to grow
@adamfeuerstein $ADXS $INCY collaborating on combo I-O study in cervical cancer is huge for I-Ocombo data.
Advaxis Forms Clinical Trial Collaboration With Incyte
Advaxis Forms Clinical Trial Collaboration With Incyte to Evaluate Investigational Combination of TwoNovel Cancer Immunotherapies for Early Stage Cervical CancerGlo
Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies
Combined Technologies to Leapfrog Clinical Pipeline of Next Generation Therapies Using Synthetic and Personalized Immunology
The Fly On The Wall
Achillion data positive, says JMP Securities »
JMP Securities believes that data recently announced by Achillion on its ACH-3102 for the treatment of hepatitis C is incrementally positive to be a buyout target.
ADAGE CAPITAL PARTNERS GP LLC ..... SC 13G, Advaxis Inc, ADXS, 2015-1-019, 2014-12-15,4,454,604, 0, new position.